[Lisuride for the prevention of migraine. Results of a multicenter study].
In an open multicenter study involving 420 patients lisuride proved to be an effective and well-tolerated migraine prophylactic. In 61.4% of the patients the frequency of migraine attacks was reduced by more than 50% during the 3 month treatment period; the severity and duration of remaining attacks were markedly reduced. In the overall assessment, the effect was regarded as good to excellent in 69.7% of the patients and tolerance was good to excellent in 94.2%. The most common side effects were nausea (4.0%), vertigo (3.1%), drowsiness (1.4%). Prognostic criteria for the response to lisuride could not be identified.
Soyka
D
D
Frieling
B
B
D000328:Adult; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008090:Lisuride / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008881:Migraine Disorders / Q000517:prevention & control*; D015337:Multicenter Studies as Topic; D011379:Prognosis
D004873:Ergolines; D008090:Lisuride
Lisurid in der Migräneprophylaxe. Ergebnisse einer multizentrischen Studie.